Under-current for the treatment of arthritis Immunodepressor Tocilizumab is approved by the World Health Organization (WHO) as a drug treatment for severely ill coronavirus, the ninth channel transmits.
According to clinical trials conducted under the auspices of the organization, the intravenous injections of Tocilizumab reduce the risk of death in patients with severe and extremely severe COVID-19 form.
The WHO website explains that the drug, being a monoclonal antibody, suppresses the excessive activity of the IL-6 receptor (interleukin 6) provoked by coronavirus, which blocking the development of the inflammatory process in the body. The report also notes that the use of tocilizumab has reduced the period of hospitalization of severely ill patients.